Can I take magnesium glycinate and ashwagandha for perimenopause sleep? I'm on an SSRI.
⚠ Safety first
[why?]
This was promoted because a governed safety rule matched the intervention and context at moderate severity. Safety items are ordered most-severe-first; nothing else displaces them.
[how serious?]
Possible additive or interfering effect; evidence is limited. Worth a clinician check before combining.
This case routes to a clinician because a modeled interaction matched your current stack/context — the engine will not silently recommend it.
Source-reported research findings
AI-extracted — pending human review. These findings retain the studied context and are not pooled treatment estimates.
PMID 38745424: PSQI
- AI-extracted — pending human review
- Extraction status: machine extracted. Source status is not human clinical review.
- Publication status: published. Record review status: not reviewed.
- Not poolable: one source-reported result, not a pooled treatment estimate.
Authors reported a direction only for sleep quality (PSQI): favours the studied intervention.
Reported p < 0.05.
- Studied combination: 1.9 mg melatonin + 200 mg elemental magnesium.
- Studied route/context: unclear.
otherwise healthy individuals with sleep disturbances; double-blinded, randomized, crossover trial. supplement condition versus placebo. sleep quality (PSQI) at 4 week intervention.
Related research with a different studied context; applicability to this question remains limited.
Source-reported direction
Source-reported direction: favours the studied intervention.
No between-arm contrast, interval estimate or pooled result is calculated here; the values above are exactly as the source reported them.
Studied context
| Participants / population | otherwise healthy individuals with sleep disturbances |
|---|---|
| Study design | double-blinded, randomized, crossover trial |
| Studied intervention | supplement condition |
| Studied combination | 1.9 mg melatonin + 200 mg elemental magnesium |
| Studied route / context | unclear |
| Comparator | placebo |
| Measured outcome | sleep quality (PSQI) |
| Timepoint | 4 week intervention |
Limitations reported for this finding
- AI-extracted; pending human review.
- A combined melatonin-magnesium intervention; no isolated ingredient effect is established.
- Crossover results lack a supported magnitude or paired uncertainty in the accepted source.
- Average PSQI scores still indicated poor sleep quality in both conditions.
Source and extraction detail
- Finding revision
- finding:pmid:38745424:psqi:between-condition:v1
- Finding version
- 1
- Finding content hash
- sha256:872d83da20f0b695fbae17cba7d48cf4cfb9a1ae9cd6542c9a43b7b753802fcd
- Paper version
- 2
- Paper version content hash
- sha256:08de6964245b14f063c6e5be09c444866724662db48f96d21e63b9c375a1714d
- Source content hash
- sha256:7eb923eead09c74399772ed1392e693e2b2a9840938e04e47436e0bd9d4836f9
- Extraction policy
- reported-findings-initial2-v1
- Extraction policy hash
- sha256:c0d84a3eafb1f7e7f5c4931e65dc3d9d9301f05110e8db8b8718d2b734ec5563
- Extraction method version
- source-grounded-reported-findings-v1
- Field locators
- reportedDirection → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=38745424&rettype=abstract&retmode=text: Abstract; authors-reported result; reportedSignificance.value → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=38745424&rettype=abstract&retmode=text: Abstract; authors-reported result; applicability.population → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=38745424&rettype=abstract&retmode=text: Abstract; authors-reported result; applicability.experimentalIntervention → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=38745424&rettype=abstract&retmode=text: Abstract; authors-reported result; applicability.experimentalInterventionComponents → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=38745424&rettype=abstract&retmode=text: Abstract; authors-reported result; applicability.comparator → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=38745424&rettype=abstract&retmode=text: Abstract; authors-reported result; applicability.design → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=38745424&rettype=abstract&retmode=text: Abstract; authors-reported result; applicability.outcomeConstruct → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=38745424&rettype=abstract&retmode=text: Abstract; authors-reported result; applicability.instrument → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=38745424&rettype=abstract&retmode=text: Abstract; authors-reported result; applicability.participantMetric → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=38745424&rettype=abstract&retmode=text: Abstract; authors-reported result
Source documents
- https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=38745424&rettype=abstract&retmode=text — sha256:7eb923eead09c74399772ed1392e693e2b2a9840938e04e47436e0bd9d4836f9 (reportedDirection → Abstract; authors-reported result; reportedSignificance.value → Abstract; authors-reported result; applicability.population → Abstract; authors-reported result; applicability.experimentalIntervention → Abstract; authors-reported result; applicability.experimentalInterventionComponents → Abstract; authors-reported result; applicability.comparator → Abstract; authors-reported result; applicability.design → Abstract; authors-reported result; applicability.outcomeConstruct → Abstract; authors-reported result; applicability.instrument → Abstract; authors-reported result; applicability.participantMetric → Abstract; authors-reported result; timepoint → Abstract; intervention duration; association-combination → Abstract; combined intervention; association-combination → Abstract; combined intervention; association-combination → Abstract; combined intervention; association-outcome → Abstract; authors-reported result)
Read the full paper explanation →Original source · Bring into My Profile
PMID 39138397: ISI
- AI-extracted — pending human review
- Extraction status: machine extracted. Source status is not human clinical review.
- Publication status: published. Record review status: not reviewed.
- Not poolable: one source-reported result, not a pooled treatment estimate.
Authors reported insomnia severity (ISI) as Mg sulphate group 17.45 score and Control group 22.4 score, each summarised separately.
Reported p < 0.001.
- Studied route/context: intravenous.
patients undergoing lumbar fixation; randomized controlled trial. Magnesium sulphate versus general anesthesia. insomnia severity (ISI) at 2 weeks after surgery.
Related research with a different studied context; applicability to this question remains limited.
Reported arm summaries
| Study arm | Reported value | Dispersion | Participants |
|---|---|---|---|
| Mg sulphate group | 17.45 score | SD 4.32 | n=40 |
| Control group | 22.4 score | SD 3.29 | n=40 |
No between-arm contrast, interval estimate or pooled result is calculated here; the values above are exactly as the source reported them.
Studied context
| Participants / population | patients undergoing lumbar fixation |
|---|---|
| Study design | randomized controlled trial |
| Studied intervention | Magnesium sulphate |
| Studied route / context | intravenous |
| Comparator | general anesthesia |
| Measured outcome | insomnia severity (ISI) |
| Timepoint | 2 weeks after surgery |
Limitations reported for this finding
- AI-extracted; pending human review.
- Lumbar-fixation surgery and intraoperative magnesium sulphate adjunct to general anaesthesia; not oral supplementation.
- Raw arm summaries at two weeks after surgery; not change scores or the adjusted regression coefficient.
- Analysis-population and adjustment details are not established by this descriptive extraction; no pooled effect or certainty upgrade.
Source and extraction detail
- Finding revision
- finding:pmid:39138397:isi:postoperative-two-weeks:v1
- Finding version
- 1
- Finding content hash
- sha256:38d9f5892c47e85982a8771ac7f604220ea728aa033ee0d13bf28c62dac2257b
- Paper version
- 2
- Paper version content hash
- sha256:dd3bc7bade8b84173b4ecfbb47525a9c6860c70bd9a0d4767e15c904a9cb201c
- Source content hash
- sha256:7a50003b05a8c9c02f3dd5dd52359b0e278f4c8efa0b850d02ba8da68ee45a92
- Extraction policy
- reported-findings-initial2-v1
- Extraction policy hash
- sha256:c0d84a3eafb1f7e7f5c4931e65dc3d9d9301f05110e8db8b8718d2b734ec5563
- Extraction method version
- source-grounded-reported-findings-v1
- Field locators
- applicability.population → https://pmc.ncbi.nlm.nih.gov/articles/PMC11320981/: Abstract; authors-reported result; applicability.experimentalIntervention → https://pmc.ncbi.nlm.nih.gov/articles/PMC11320981/: Abstract; authors-reported result; applicability.experimentalInterventionRoute → https://pmc.ncbi.nlm.nih.gov/articles/PMC11320981/: Abstract; authors-reported result; applicability.comparator → https://pmc.ncbi.nlm.nih.gov/articles/PMC11320981/: Abstract; authors-reported result; applicability.design → https://pmc.ncbi.nlm.nih.gov/articles/PMC11320981/: Abstract; authors-reported result; applicability.instrument → https://pmc.ncbi.nlm.nih.gov/articles/PMC11320981/: Abstract; authors-reported result; applicability.outcomeConstruct → https://pmc.ncbi.nlm.nih.gov/articles/PMC11320981/: Abstract; authors-reported result; applicability.participantMetric → https://pmc.ncbi.nlm.nih.gov/articles/PMC11320981/: Table 2; postoperative ISI; experimental.armLabel → https://pmc.ncbi.nlm.nih.gov/articles/PMC11320981/: Table 2; column header; comparator.armLabel → https://pmc.ncbi.nlm.nih.gov/articles/PMC11320981/: Table 2; column header; experimental.n → https://pmc.ncbi.nlm.nih.gov/articles/PMC11320981/: Table 2; experimental column n; comparator.n → https://pmc.ncbi.nlm.nih.gov/articles/PMC11320981/: Table 2; control column n; experimental.mean → https://pmc.ncbi.nlm.nih.gov/articles/PMC11320981/: Table 2; ISI; experimental mean; experimental.dispersion.value → https://pmc.ncbi.nlm.nih.gov/articles/PMC11320981/: Table 2; ISI; experimental SD; comparator.mean → https://pmc.ncbi.nlm.nih.gov/articles/PMC11320981/: Table 2; ISI; control mean; comparator.dispersion.value → https://pmc.ncbi.nlm.nih.gov/articles/PMC11320981/: Table 2; ISI; control SD; experimental.unit → https://pmc.ncbi.nlm.nih.gov/articles/PMC11320981/: Methods; ISI scale; comparator.unit → https://pmc.ncbi.nlm.nih.gov/articles/PMC11320981/: Methods; ISI scale; reportedSignificance.value → https://pmc.ncbi.nlm.nih.gov/articles/PMC11320981/: Table 2; ISI; p-value
Source documents
- https://pmc.ncbi.nlm.nih.gov/articles/PMC11320981/ — sha256:7a50003b05a8c9c02f3dd5dd52359b0e278f4c8efa0b850d02ba8da68ee45a92 (applicability.population → Abstract; authors-reported result; applicability.experimentalIntervention → Abstract; authors-reported result; applicability.experimentalInterventionRoute → Abstract; authors-reported result; applicability.comparator → Abstract; authors-reported result; applicability.design → Abstract; authors-reported result; applicability.instrument → Abstract; authors-reported result; applicability.outcomeConstruct → Abstract; authors-reported result; applicability.participantMetric → Table 2; postoperative ISI; experimental.armLabel → Table 2; column header; comparator.armLabel → Table 2; column header; experimental.n → Table 2; experimental column n; comparator.n → Table 2; control column n; experimental.mean → Table 2; ISI; experimental mean; experimental.dispersion.value → Table 2; ISI; experimental SD; comparator.mean → Table 2; ISI; control mean; comparator.dispersion.value → Table 2; ISI; control SD; experimental.unit → Methods; ISI scale; comparator.unit → Methods; ISI scale; reportedSignificance.value → Table 2; ISI; p-value; timepoint → Methods; ISI assessment time; association-intervention → Abstract; authors-reported result; association-outcome → Abstract; authors-reported result)
Read the full paper explanation →Original source · Bring into My Profile
Studied contexts, side by side
These studies measured their own outcomes in their own populations. Differences between columns are differences in what was studied — not a ranking, and not a head-to-head result.
| Studied context | PMID 38745424: PSQI | PMID 39138397: ISI |
|---|---|---|
| Participants / population | otherwise healthy individuals with sleep disturbances | patients undergoing lumbar fixation |
| Study design | double-blinded, randomized, crossover trial | randomized controlled trial |
| Studied intervention | supplement condition | Magnesium sulphate |
| Studied combination | 1.9 mg melatonin + 200 mg elemental magnesium | not reported |
| Studied route / context | unclear | intravenous |
| Comparator | placebo | general anesthesia |
| Measured outcome | sleep quality (PSQI) | insomnia severity (ISI) |
| Timepoint | 4 week intervention | 2 weeks after surgery |
| Source-reported result | Authors reported a direction only for sleep quality (PSQI): favours the studied intervention. Reported p < 0.05. | Authors reported insomnia severity (ISI) as Mg sulphate group 17.45 score and Control group 22.4 score, each summarised separately. Reported p < 0.001. |
Question interpreted as
Ashwagandha and Magnesium for sleep
- Population
- not specified in the reviewed claim
- Comparator
- not specified in the reviewed claim
- Time
- not specified in the reviewed claim
- Form and dose
- not specified in the reviewed claim
Decision summary
What this answer means
- small, early-stage effect on sleep (grade C, low certainty).
- A safety concern limits this action: Ashwagandha with an SSRI may carry additive sedative/serotonergic risk; evidence is limited.
- The studied population for this evidence has not been structured yet. We cannot judge if it applies to you.
- This reflects general evidence only. It is not advice made just for you.
Evidence, safety, personal fit and action are separate judgments. Open the sections below to inspect each one.
For your question
small, early-stage effect on sleep
[see studies]
The grade (grade C) reflects the combined weight of these sources; certainty (low) is the engine's separate read on how confident to be — never the same thing.
Efficacy and Safety of Ashwagandha (Withania somnifera) Root Extract in Insomnia and Anxiety: A Double-blind, Randomized, Placebo-controlled Study · peer-reviewed · PMID:31728244 · DOI:10.7759/cureus.5797Contradictory evidence
No contradicting evidence recorded for this claim.
may modestly reduce sleep-onset latency in older adults with insomnia, but the evidence is limited and low quality; benefit for general adults or magnesium glycinate specifically is uncertain
[see studies]
The grade (grade C) reflects the combined weight of these sources; certainty (low) is the engine's separate read on how confident to be — never the same thing.
The Role of Magnesium in Sleep Health: a Systematic Review of Available Literature · peer-reviewed · PMID:35184264 · DOI:10.1007/s12011-022-03162-1Oral magnesium supplementation for insomnia in older adults: a Systematic Review & Meta-Analysis · peer-reviewed · PMID:33865376 · DOI:10.1186/s12906-021-03297-zContradictory evidence
No contradicting evidence recorded for this claim.
Products and quality
No commercial product or batch was assessed. Ingredient evidence does not establish that a brand has the studied form or dose, contains what its label claims, or has been independently tested.
Monitoring and follow-up
A validated personal monitoring plan is not recorded for this claim. If you act on the general evidence, decide in advance what sleep outcome matters to you and discuss unresolved safety questions with a clinician or pharmacist.
People say · Evidence shows
“Magnesium glycinate is better for sleep because it crosses the blood-brain barrier”
[explain]
popularity / assertion runs ahead of the evidence.
Belief direction is the position of the belief relative to the evidence; magnitude combines the grade-distance, whether the evidence state is unflattering to the assertion, and the claim-type penalty for speculation or marketing language (rubric: Doc 17 §2.3).
The belief never inherits the evidence's grade — by axiom B4. Speculation that outruns the data does not get credit for the data.
“Ashwagandha balances cortisol”
[explain]
popularity / assertion runs ahead of the evidence.
Belief direction is the position of the belief relative to the evidence; magnitude combines the grade-distance, whether the evidence state is unflattering to the assertion, and the claim-type penalty for speculation or marketing language (rubric: Doc 17 §2.3).
The belief never inherits the evidence's grade — by axiom B4. Speculation that outruns the data does not get credit for the data.
What the label may legally say
“Helps the body adapt to stress”
“Supports muscle and nerve function”
A legal label claim — it does not have to be proven and is not the same as evidence. We keep “people say,” “the law permits,” and “the evidence shows” visibly separate.
Trending?
magnesium — evidence and attention roughly aligned · ashwagandha — attention is ahead of the evidence
[hype vs evidence]
The hype position is the L4 read: where an intervention sits on the emerging → settled → debunked arc. A surging position with thin evidence is the classic gap; a settled position with B-grade evidence means attention and proof are roughly aligned.
What I don't know about you
- which specific SSRI and dose
- pregnancy status
- liver status
Knowing these would sharpen the safety check and the answer. They're session-scoped only — never stored as a profile.
Making your decision
Here’s what would change this advice: which specific SSRI and dose · pregnancy status · liver status · Larger, independently replicated studies that reduce the current uncertainty. · A structured studied population and applicability assessment. · A reviewed dose and formulation that can be matched to the intervention used. · A recorded comparator and time horizon for the reviewed claim..
This is information to support your decision — not a verdict, and not a substitute for your clinician.
Compare other options
These are evidence comparisons for the same outcome, not personalized recommendations.
Melatonin
reduces time to fall asleep; best for circadian timing
Melatonin with an SSRI: possible additive sedation; evidence is thin.
Inspect evidence5-HTP
limited evidence for sleep; serotonergic, so caution with antidepressants
5-HTP raises serotonin; with an SSRI this risks serotonin syndrome. Do not combine without medical supervision.
Inspect evidenceGlycine
small trials suggest improved subjective sleep quality and reduced next-day fatigue
Safety has not been established by this answer. No safety rule firing does not mean there is no risk.
Inspect evidenceValerian
evidence is genuinely mixed: some low-quality trials report small improvements in subjective sleep quality, but the most rigorous reviews find no significant difference from placebo. Considered safe; not reliably effective.
Safety has not been established by this answer. No safety rule firing does not mean there is no risk.
Inspect evidenceWhat this answer assessed
Broad questions are split into separate decision claims so an evidence answer is not mistaken for a product, dose, or safety answer.
- efficacy — answered. Answered from the governed canonical evidence claim. Evidence record.
- dose sufficiency — not assessed. A studied dose is recorded, but no intended dose was provided for comparison. Evidence record.
- form equivalence — unavailable. No reviewed studied form is recorded. Evidence record.
- labeling accuracy — unavailable. No exact product was supplied, so labeling accuracy cannot be assessed. Evidence record.
- interaction safety — not assessed. No governed safety review or context-specific fired rule is recorded, so safety is not assessed. Evidence record.
- applicability — unavailable. The studied population for this evidence has not been structured yet. We cannot judge if it applies to you. Evidence record.
- comparative effectiveness — answered. Canonical alternatives for the same outcome were compared. Evidence record.
- efficacy — answered. Answered from the governed canonical evidence claim. Evidence record.
- dose sufficiency — unavailable. No reviewed studied dose is recorded. Evidence record.
- form equivalence — unavailable. No reviewed studied form is recorded. Evidence record.
- labeling accuracy — unavailable. No exact product was supplied, so labeling accuracy cannot be assessed. Evidence record.
- interaction safety — answered. One or more deterministic safety rules fired for this intervention and context. Evidence record.
- applicability — unavailable. The studied population for this evidence has not been structured yet. We cannot judge if it applies to you. Evidence record.
- comparative effectiveness — answered. Canonical alternatives for the same outcome were compared. Evidence record.
Full audit trail
This trace summarizes the recorded composition stages. The audit fields identify the canonical claims, sources, policy, and model versions used.
- resolve: interventions=[mg, ash] outcome=sleep lifeStage=perimenopause meds=[ssri]
- retrieve: 2 evidence claim(s)
- contrast: 2 belief(s) with computed gaps
- safety-gate: 1 promoted; blocklist=[none]
- time: {"Magnesium":"settled","Ashwagandha":"surging"}
- law-permits: 2 label claim(s)
- applicability: cannot-determine (ec_ash_sleep)
- alternatives: ec_mel_sleep, ec_5htp_sleep, ec_gly_sleep, ec_val_sleep
- decompose: 14 atomic decision claim(s) assessed
model slice-0.1.0 · as of 2026-10-05T21:17:25.237Z